The BOW Project

The main objective of BOW is to create hybrid magnetic nanoparticles with a membrane surface made from an extracellular vesicle. This innovative approach “dresses” synthetic magnetic nanoparticles with biological membranes derived from EVs to confer biomimetic functions such as immune evasion and enhanced targeting, paving the way for safer and more effective nanomaterials in medicine. Successful development of these hybrid nanodevices could advance precision therapies and support the clinical translation of implantable nanotechnologies with improved biocompatibility and performance.

HansaBioMed participated in optimization of EV production as well as verification of EV purity and quality (integrity, stability, and activity) to be assessed at each step of EV production scale up and engineering. HBM also performed in vitro tropism testing preceding definition of administration protocols for in vivo testing (doses and timeline).

HansaBioMed Life Sciences, Consorzio interuniversitario per lo sviluppo dei Sistemi a Grande Interfase (CSGI), Consiglio Nazionale Delle Ricerche, Universidad de Santiago de Compostela, Max-Planck-Institut für Polymerforschung, Zabala Innovation, Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt, Atlantic Technological University, ETH Zurich, Biodevice Systems Sro, Università degli studi di Modena e Reggio Emilia